[en] During the nineties, a controversy was noted in the literature about the potential risk of using calcium antagonists in the treatment of hypertension. Several recent studies, such as the INSIGHT’s one have not confirmed this provided that one uses long-acting molecule. But the real beneficial effect due to the different antihypertensive classes is mainly linked to the magnitude of the blood pressure lowering effect. [fr] Une controverse s’est installée dans les années 90 concernant le risque potentiel d’utilisation des antagonistes calciques dans le traitement de l’hypertension artérielle. Plusieurs études récentes, dont l’étude INSIGHT commentée ici, ont infirmé ce risque à condition d’utiliser des molécules à longue durée d’action. Il ressort cependant que le bénéfice à attendre des molécules antihypertensives passe avant tout par l’importance de l’abaissement tensionnel observé.
Disciplines :
Urology & nephrology
Author, co-author :
Krzesinski, Jean-Marie ; Université de Liège - ULiège > Département des sciences cliniques > Néphrologie
Language :
French
Title :
Les antagonistes calciques ont-ils bien une place de première ligne dans le traitement de l'hypertension artérielle?
Alternative titles :
[en] Have calcium antagonists a first line place for the treatement of arterial hypertension?
La place des médicaments dans le traitement de l'hypertension (2001) Folia Pharmaceutica, p. 11
Krzesinski, J.-M., Rorive, G.L., Les antagonistes des flux calciques dans le traitement de l'hypertension artérielle (1984) Rev Med Liège, 39, pp. 232-237
Collins, R., Peto, R., MacMahon, S., Blood pressure, stroke and coronary heart disease (1990) Lancet, 335, pp. 827-838
MacMahon, S., Peto, R., Cutler, J., Blood pressure, stroke and coronary heart disease. Part 1, prolonged differences in blood pressure: Prospective observational studies corrected for the regression dilution bias (1990) Lancet, 335, pp. 765-774
1999 World Health Organization-International Society of hypertension guidelines for the management of hypertension (1999) J Hypertens, 17, pp. 151-183
Effects of calcium antagonists on the risks of coronary heart disease, cancer and bleeding (1997) J Hypertens, 15, pp. 105-115
Neaton, J., Grimm, R., Prineas, R., Treatment of mild hypertension study. Final study (1993) JAMA, 270, pp. 713-724
Abernethy, D., Schwartz, J.B., Calcium-antagonist drugs (1999) N Engl J Med, 341, pp. 1447-1457
Alderman, M.H., Cohen, H., Roqué, R., Madhavan, S., Effect of long-acting and short-acting calcium antagonists on cardiovascular outcomes in hypertensives patients (1997) Lancet, 349, pp. 594-598
Gong, L., Zhang, W., Zhu, Y., Shanghai trial of nifedipine in the elderly (STONE) (1996) J Hypertens, 14, pp. 1237-1245
Staessen, J.A., Fagard, R., Thijs, L., Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension (1997) Lancet, 350, pp. 757-764
Brown, M.J., Palmer, C.R., Castaigne, A., Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT) (2000) Lancet, 356, pp. 366-372
Brown, M.J., Palmer, C.R., Castaigne, A., Principal results from the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT) (2001) Eur Heart J, 3 (SUPPL. B), pp. B20-B26
Chobanian, A.V., Can antihypertensive drugs reduce atherosclerosis and its clinical complications? (1994) Am J Hypertens, 7, pp. 119S-125S
Simon, A., Gariépy, J., Moyse, D., Differential effects of nifedipine and co-amilozide on the progression of early carotid wall changes (2001) Circulation, 103, pp. 2949-2954
Motro, M., Shemesh, J., Calcium channel blocker nifidepine slows down progression of coronary calcification in hypertensive patients compared with diuretics (2001) Hypertension, 37, pp. 1410-1413
Estacio, R., Jeffers, B., Hiat, W., The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension (1998) N Engl J Med, 338, pp. 645-652
Tuomilehto, J., Rastenyte, D., Birkenhäger, W., Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension (1999) N Engl J Med, 340, pp. 677-684
O'Leary, D.H., Polak, J.F., Kronmal, R.A., Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults (1999) N Engl J Med, 340, pp. 14-22
Borhani, N.O., Mercuri, M., Borhani, P.A., Final outcome results of the multicenter Isradipine diuretic atherosclerosis study (MIDAS) (1996) JAMA, 276, pp. 785-791
Borhani, N.O., (1995) Calcium antagonists and atherosclerosis: current status, new directions, pp. 545-548. , Elsevier Science BV
Pitt, B., Byington, R.P., Furberg, C.D., Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events (2000) Circulation, 102, pp. 1503-1510
Waters, D., Lespérance, J., Francetich, M., A controlled clinical trial to assess the effect of a calcium channel blocker on the progression of coronary atherosclerosis (1990) Circulation, 82, pp. 1940-1953
Hansson, L., Hedner, T., Lund-Johansen, P., Effects of calcium antagonists compared with diuretics and β-blockers on cardiovascular morbidity and mortality in hypertension: The Nordic Diltiazem (NORDIL) study (2000) Lancet, 356, pp. 359-365
Hansson, L., Lingholm, L.H., Niskanen, L., Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Captopril Prevention Project (CAPPP) randomised trial (1999) Lancet, 353, pp. 611-616
MacMahon, S., Neal, B., Differences between blood-pressure-lowering drugs (2000) Lancet, 356, pp. 352-353
Hansson, L., Lindholm, L.H., Ekbom, T., Randomised trial of old and new antihypertensive drugs in elderly patients: Cardiovascular mortality and morbidity the Swedish trial in old patients with hypertension-2 study (1999) Lancet, 354, pp. 1751-1756
Ruilope, L., Schifffrin, E., Blood pressure control and benefits of antihypertensive therapy - Does it make a difference which agents we use? (2001) Hypertension, 38 (PART 2), pp. 537-542
Staessen, J.A., Wang, J.I.-G., Thijs, L., Cardiovascular protection and blood pressure reduction (2001) Lancet, 358, pp. 1305-1315
This website uses cookies to improve user experience. Read more
Save & Close
Accept all
Decline all
Show detailsHide details
Cookie declaration
About cookies
Strictly necessary
Performance
Strictly necessary cookies allow core website functionality such as user login and account management. The website cannot be used properly without strictly necessary cookies.
This cookie is used by Cookie-Script.com service to remember visitor cookie consent preferences. It is necessary for Cookie-Script.com cookie banner to work properly.
Performance cookies are used to see how visitors use the website, eg. analytics cookies. Those cookies cannot be used to directly identify a certain visitor.
Used to store the attribution information, the referrer initially used to visit the website
Cookies are small text files that are placed on your computer by websites that you visit. Websites use cookies to help users navigate efficiently and perform certain functions. Cookies that are required for the website to operate properly are allowed to be set without your permission. All other cookies need to be approved before they can be set in the browser.
You can change your consent to cookie usage at any time on our Privacy Policy page.
